Amphetamine-type agents interact with the vesicular monoamine transporter type 2 (VMAT 2 ), promoting the release of intravesicular neurotransmitter and an increase in cytoplasmic neurotransmitter. Some compounds, such as reserpine, "release" neurotransmitter by inhibiting the ability of VMAT 2 to accumulate neurotransmitter in the vesicle, whereas other types of compounds can release neurotransmitter via a carriermediated exchange mechanism. The purpose of this study was to determine, for 42 mostly amphetamine-related compounds, their mode of interaction with the VMAT 2 . We used a crude vesicular fraction prepared from rat caudate to assay VMAT 2 activity. Test compounds were assessed in several assays, including 1) inhibition of findings derive from this comprehensive study. First, our work indicates that most agents are VMAT 2 substrates. Second, our data strongly suggest that amphetamine-type agents deplete vesicular neurotransmitter via a carrier-mediated exchange mechanism rather than via a weak base effect, although this conclusion needs to be confirmed via direct measurement of vesicular pH. Third, our data fail to reveal differential VMAT 2 interactions among agents that do and do not produce longterm 5-hydroxytryptamine depletion. Fourth, the data reported revealed the presence of two pools of [ 3 H]amine within the vesicle, one pool that is free and one pool that is tightly associated with the ATP/protein complex that helps store amine. Finally, the VMAT 2 assays we have developed should prove useful for guiding the synthesis and evaluation of novel VMAT 2 agents as possible treatment agents for addictive disorders.
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The vesicular monamine transporter type 2 (VMAT 2 ) pumps its substrates dopamine, serotonin, norepinephrine, epinephrine, and histamine into vesicular storage vesicles against a gradient. This process is powered by the vesicular H ϩ -ATPase and the exchange of two intravesicular protons for one substrate molecule (Schuldiner et al., 1998) . Once in the vesicle, substrates form a complex with ATP proteins, which may account for the very high concentrations of substrates in the granule (Cooper et al., 2003) . Although much is known about the bioenergetics of VMAT 2 function, less is known about the interactions of a wide array of amphetamine-related compounds at VMAT 2 (Schuldiner et al., 1995; Perera et al., 2003) . In contrast, much more is known about how a variety of different agents interact with the plasma biogenic amine transporters, as uptake inhibitors or as substrates, also termed releasers . Reuptake inhibitors bind to transporter proteins, but they are not themselves transported. These drugs elevate extracellular transmitter concentrations by blocking transporter-mediated recapture of transmitter molecules from the synapse. Substrate-type releasers bind to transporter proteins, and these drugs are subsequently transported into the cytoplasm of nerve terminals. Releasers elevate extracellular transmitter concentrations by a two-pronged mechanism: 1) they promote efflux of transmitter by a process of transporter-mediated exchange, and 2) they increase cytoplasmic levels of transmitter by disrupting storage of transmitters in vesicles (Rudnick and Clark, 1993; Rudnick, 1997) . This latter action increases the pool of neurotransmitter available for release by transporter-mediated exchange. Because substrate-type releasing agents must be transported into nerve terminals to promote transmitter release, reuptake inhibitors can block the effects of releasers. With appropriate assay methods that assess both the uptake and releasing properties of test agents, new insights are possible. For example, whereas (ϩ)-pseudophenmetrazine is a dopamine transporter substrate, (Ϫ)-pseudophenmetrazine is a dopamine transporter inhibitor (Rothman et al., 2002) .
Our laboratory previously characterized the interaction of a wide range of amphetamine-like agents at the biogenic amine transporters (Rothman et al., , 2002 . In these studies, we developed methods that determined whether the test compound is a substrate or inhibitor of the transporter. The major purpose of this study was to determine the mode of interaction (VMAT 2 substrate or inhibitor) for a wide range of test compounds. Toward this end, we developed methods that allow the relatively rapid determination of substrate versus inhibitor activities of test compounds using three major endpoints: 1) inhibition of 
Materials and Methods
Preparation of a Crude Vesicular Fraction. Rat caudate was dissected from frozen rat brains purchased from Pel-Freez (Rogers, AR). A crude vesicular fraction was prepared from rat caudate putamen with minor modifications of published procedures (Teng et al., 1998) . Freshly excised caudates were homogenized for 30 s in 0.32 M sucrose using a Polytron (Brinkmann Instruments, Westbury, NY) and spun at 800g for 12 min at 4°C. The pellet was discarded and synaptosomal fragments in the supernatant were pelleted by centrifugation at 22,000g for 15 min at 4°C (P2). The pellet was diluted to 8 ml with distilled water and homogenized with 6 strokes of a Potter-Elvehjem tissue grinder. Reagents were added to yield the following final concentrations: 25 mM HEPES, 100 mM potassium tartrate, 5 mM MgCl 2 , 10 mM NaCl, 1.7 mM L-ascorbic acid, 0.05 mM EGTA, 0.1 mM EDTA, and 100 M pargyline, pH 7.4 (binding buffer) in a final volume of 10 ml.
[ 3 H]Dihydrotetrabenazine Binding. [ 3 H]DHTBZ was used to label synaptosomal vesicles from rat caudate putamen with minor modifications of published procedures (Teng et al., 1998) . Crude vesicles, prepared as described above, were added to 12-ϫ 75-mm polystyrene test tubes prefilled with 300 l of binding buffer containing test drugs and 2 nM [ 3 H]DHTBZ (20 Ci/mmol). Assays were terminated after 4 h at 25°C by rapid vacuum filtration over GF/B filters presoaked in ice-cold 2% polyethyleneimine followed by two rinse cycles with ice-cold binding buffer without pargyline, using a model M-48 cell harvester (Brandel Inc., Gaithersburg, MD). Radioactivity retained on filters was quantified by a Taurus (Micromedic, Huntsville, AL) liquid scintillation counter at 40% efficiency. Nonspecific binding was determined in the presence of 20 M tetrabenazine. Control experiments showed that binding was saturable with respect to time and was proportional to protein concentration (data not shown).
VMAT 2 Uptake and Release Assays. Crude synaptic vesicles were prepared as described above. P2 preparations were diluted to 8 ml with ice-cold distilled water, they were homogenized with 6 strokes of a Potter-Elvehjem tissue grinder, and then they were incubated on ice for 30 min followed by centrifugation at 22,000g for 15 min at 4°C. The pellet was discarded and the supernatant (S3) was restored to osmolality in a volume of 10 ml by adding concentrated solutions to create the uptake buffer: 25 mM HEPES, 100 mM potassium tartrate, 1.7 mM L-ascorbic acid, 0.05 EGTA, 0.1 mM EDTA, 2 mM Mg-ATP, 1 M indatraline, and 0.1 mM pargyline, pH 7.4. Buffered S3 was incubated at 25°C for 15 min before use. VMAT 2 uptake assays were performed in 96-well plates. Each well was preloaded with 50 l of uptake buffer or test drug at the appropriate concentration and 200 l of 60 nM [ 3 H]dopamine in uptake buffer. The reaction was initiated by addition of 250 l of tissue preparation (20 g of protein) and stopped after 5 min by rapid vacuum filtration over GF/B filters presoaked in 2% polyethyleneimine, using a model MWR-96T-4 cell harvester (Brandel Inc.). Filters were washed twice with 2 ml of ice-cold uptake buffer without indatraline and pargyline and with 2 mM MgSO 4 instead of Mg-ATP. Radioactivity retained on filters was quantified using a Trilux (PerkinElmer Life and Analytical Sciences, Boston, MA) liquid scintillation counter at 40% efficiency. Dopamine (100 M) was used to determine nonspecific activity. Control experiments showed that the uptake of [ 3 H]dopamine was saturable with respect to time, it was proportional to protein concentration, and it was entirely dependent on the presence of ATP (data not shown).
For , and samples were processed as described for the uptake assay. Nonspecific activity was determined in the presence of 100 M dopamine. This value was subtracted from the other values to yield a "specific" activity. To determine the rate of dopamineinduced efflux of [ 3 H]amine, vesicles were prepared as described above for the release assays, and the amount of retained [ 3 H]amine was measured at several time points after the addition of 1 M dopamine.
Experimental Design, Data Analysis, and Statistics. Inhibition/release curves were generated using eight drug concentrations per curve. For [ 3 H]dopamine uptake inhibition assays and [ 3 H]DHTBZ binding, the data of three independent experiments were pooled and fit to the two-parameter logistic (eq. 1) using MLAB-PC (Civilized Software, Bethesda, MD), as described previously , for the best-fit estimates of the IC 50 and slope factor. For release assays, the data were calculated as a percentage of inhibition and then fit to eq. 2 for the best-fit estimates of the EC 50 and plateau level (E MAX ), using either MLAB-PC or KaleidaGraph 3.6 software (Synergy Software, Reading, PA). Graphs were generated with KaleidaGraph 3.6 software. The equations used are as follows:
To determine the K M and V MAX of [ 3 H]dopamine and [ 3 H]tyramine uptake, each radioligand was displaced with either dopamine or tyramine, and the pooled data of three experiments were fit to the Michaelis-Menten equation for the best-fit estimate of the V MAX and K M . Dopamine-induced efflux of [ 3 H]amine data were fit to a monoexponential decay equation for the best-fit estimates of the K off (Rothman et al., 1991 3 H]dihydrotetrabenazine (20 Ci/mmol), and tetrabenazine were purchased from American Radiolabeled Chemicals (St. Louis, MO). Ketanserin, reserpine, dopamine, norepinephrine, tyramine, parachloroamphetamine, metachlorophenylpiperazine, and trifluoromethylphenylpiperazine were purchased from Sigma/RBI (Natick, MA). Histamine and 5-hydroxytryptamine were purchased from Sigma-Aldrich (St. Louis, MO). (ϩ)-Norfenfluramine, (Ϫ)-norfenfluramine, and (Ϯ)-norfenfluramine were a gift from SRI International (Menlo Park, CA). All other drugs in the study were provided by the Addiction Research Center Pharmacy (National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD). The sources of other reagents are published . 1.7 M (norepinephrine). This pattern of activity is similar to that observed for the plasma membrane biogenic amine transporters, where uptake blockers inhibit both biogenic amine transporter binding and function, and substrates inhibit function much more potently than they inhibit transporter binding (Rothman et al., 1999 3 H]dopamine uptake ranged from 0.5 M for 1-napthyl-2-aminopropane to 92 M for (ϩ)-pseudophenmetrazine. It is noteworthy that these agents are all much more potent at the plasma membrane biogenic amine transporters than at the VMAT 2 (Rothman et al., , 2002 . Interestingly, histamine, although generally thought to be a substrate for VMAT 2 , was very weak in both assays.
Results
[ Via what is termed the "weak base" effect, amphetaminetype agents can deplete vesicular biogenic amine content by degrading the pH gradient that powers the transporter (Sulzer and Rayport, 1990) . To determine whether this effect occurred under our assay conditions, we compared the effects of (ϩ)-amphetamine and NH 4 Cl on vesicular [
3 H]dopamine release. As reported in Fig. 4, (ϩ) -amphetamine, at micromolar concentrations, reduced retained [ 3 H]dopamine in a dosedependent manner, reaching a plateau at approximately 40% of control. In contrast, NH 4 Cl, at millimolar concentrations, reduced retained [ 3 H]dopamine below the "nonspecific" level determined with 100 M dopamine. (ϩ)-Amphetamine (100 M) and NH 4 Cl (100 M and 5 mM) did not alter the pH of the buffer. H͔dopamine uptake inhibition curves were generated with tyramine or dopamine, respectively. The data of three experiments (n ϭ 48 points) were pooled and fit to the Michaelis-Menton equation for the best-fit estimates of the V MAX and K M . 
Discussion
The VMAT 2 is a long-studied transporter that serves to concentrate its substrates, the biogenic amines, in storage vesicles (Schuldiner et al., 1998; Cooper et al., 2003; Sulzer et al., 2005) . Amphetamine-type drugs interact with the VMAT 2 (Schuldiner et al., 1993) in a complex manner (for review, see Fleckenstein and Hanson, 2003) . Amphetamines can inhibit VMAT 2 function via competitive blockade (Gonzalez et al., 1994) and also deplete vesicular biogenic amine content by degrading the pH gradient that powers the transporter (Sulzer and Rayport, 1990) . In addition, amphetamine alters the distribution of vesicles between the cytoplasm and plasma membrane (Fleckenstein and Hanson, 2003) . Some evidence suggests that the ability of MDMA to release neuronal serotonin (Mlinar and Corradetti, 2003) and amphetamine to release neuronal dopamine (Jones et al., 1998 ) is dependent on release of vesicular neurotransmitter.
We previously characterized the interaction of a wide range of amphetamine-like agents at the biogenic amine transporters (Rothman et al., , 2002 , using methods that determined whether the test compound is a substrate or inhibitor of the transporter. In the present study, we sought to apply this approach to the VMAT 2 . We developed methods that allow the relatively rapid determination of substrate versus inhibitor activities of test compounds and examined the interaction of a wide range of compounds on VMAT 2 function, using three major endpoints : 1) In undertaking these experiments, we also were interested to see whether differential interactions at the VMAT 2 might distinguish between serotonin transporter substrates that produce long-term serotonin depletion (fenfluramine and MDMA) and serotonin transporter substrates that do not (mCPP and TFMPP). Our results show that most amphetamine-like agents tested are substrates for the VMAT 2 , with EC 50 values in the range of 5 to 50 M; that VMAT 2 interactions do not predict the ability of a serotonin transporter substrate to produce long-term serotonin depletion; and that most agents are much more potent at the plasma membrane biogenic amine transporters than at the VMAT 2 .
Unlike other studies that use purified synaptic vesicles (Teng et al., 1998) , we used a crude preparation of synaptic vesicles that contained 1 M indatraline to block any residual plasma membrane biogenic amine transporters. Under these conditions, we obtained data similar to those reported by others. For example, similar to our data, two groups reported that (ϩ)-amphetamine inhibited [
3 H]DHTBZ binding with an IC 50 value greater than 10 M (Rostene et al., 1992; Zucker et al., 2001) . Moreover, Teng et al. (1998) reported that (ϩ)-amphetamine released [
3 H]dopamine from purified vesicles with an EC 50 ϭ 2.2 M, a value almost identical to what we observed (2.5 M; Table 2 ).
As with the biogenic amine transporters, VMAT 2 can be assessed both by binding and functional assays. Binding assays label the transporter with a compound that inhibits the transporter ([ 3 H]DHTBZ), and functional assays measure the ability of the transporter to translocate a substrate ([ 3 H] dopamine) across the cell membrane. Our previous work with the biogenic amine transporters indicated that transporter inhibitors had similar potencies in both types of assays, whereas substrates were much more potent in the functional assay than the binding assay. Indeed, this seemed to be the case for the VMAT 2 as well (Table 1 ). Compounds NH 4 Cl, released [ 3 H]dopamine to a level below that produced by 100 M dopamine, indicating that even extraordinarily high concentrations of amphetamine-type drugs do not deplete vesicular amine via the free-base effect. For these agents to do so would probably require millimolar concentrations, which are far beyond the range they might achieve in vivo.
Some evidence suggests that the ability of MDMA to release neuronal serotonin (Mlinar and Corradetti, 2003) and amphetamine to release neuronal dopamine (Jones et al., 1998) is dependent on release of vesicular amine. Consistent with these in vivo data, our results (Table 2) indicate that (Ϯ)-amphetamine and (Ϯ)-MDMA release vesicular dopamine at the pharmacologically relevant EC 50 values of 4.3 and 27 M, respectively. In contrast, other amphetaminetype agents, such as phentermine, phenmetrazine, and 1-benzylpiperazine, are potent releasers of neuronal dopamine (Baumann et al., 2000 Rothman et al., 2002) , but they are inactive at VMAT 2 . Agents such as these may prove to be valuable control compounds for determining the importance of vesicular release for the in vivo actions of amphetamine-type agents.
Certain serotonin transporter substrates, such as fenfluramine (McCann et al., 1997) and MDMA (Green et al., 2003) , are described as "neurotoxic" based on their ability to produce, when administered at high doses, persistent decreases in markers of the presynaptic serotonin nerve terminal., although recent data strongly suggest that these agents may not cause axotomy in the rat (Rothman et al., 2003; Wang et al., 2004) . As reviewed previously, being a serotonin transporter substrate is necessary, but not sufficient, for a drug to produce long-term serotonin depletion (Rothman and Baumann, 2002a ). For example, 1-naphthyl-2-aminopropane, mCPP, and TFMPP are serotonin transporter substrates ) that do not deplete brain serotonin Rothman et al., 2005) . Thus, in the present study we explored the hypothesis that neurotoxic serotonin transporter substrates (MDMA and fenfluramine) differ from non-neurotoxic serotonin transporter substrates in their VMAT 2 interactions. As described below, the data suggest that this is not the case.
The non-neurotoxic serotonin transporter substrates (1-napthyl-2-aminopropane, TFMPP, and mCPP) differ from the neurotoxic serotonin transporter substrates [(ϩ)-MDMA and (ϩ)-fenfluramine] in their E MAX values in the [ 3 H]dopamine release assay. The former substrates have E MAX values of approximately 80 to 100%, whereas the latter substrates have E MAX values of approximately 65%. However, other compounds with known serotonin-depleting activity do not fit into this framework. For example, the E MAX value of (ϩ)-norfenfluramine (67.6%), a neurotoxic compound (Johnson and Nichols, 1990) , and parachloroamphetamine (74.4%) are similar to that of TFMPP (82.5%). Moreover, it is not clear whether some of these agents would achieve high enough concentrations in the nerve terminal to actually interact at VMAT 2 . For example, the high concentrations of the piperazine serotonin transporter substrates needed to affect VMAT 2 function (ϳ20 M) compared with their potency as serotonin transporter substrates (30 -60 nM) (Rothman and Baumann, 2002b; Baumann et al., 2005) suggests that this mechanism might not occur in vivo.
In summary, our comprehensive study of the interaction of 42 mostly amphetamine-related agents with VMAT 2 has led to several important findings. First, our work indicates that most agents are VMAT 2 substrates. Second, our data strongly suggest that amphetamine-type agents deplete vesicular neurotransmitter via a carrier-mediated exchange mechanism rather than via the weak base effect, although this conclusion needs to be confirmed via direct measurement of vesicular pH. Third, our data fail to reveal differential VMAT 2 interactions among agents that do and do not produce long-term 5-HT depletion. Fourth, the data revealed the presence of two pools of [ 3 H]amine within the vesicle, one pool that is free and one pool that is tightly associated with the ATP/protein complex that helps store amine. Finally, the VMAT 2 assays we have developed should prove useful for guiding the synthesis and evaluation of novel VMAT 2 agents as possible treatment agents for addictive disorders (Miller et al., 2004) .
